secwatch.observer — SEC 8-K summary
======================================

Issuer:     Moleculin Biotech, Inc. (MBRX)
CIK:        0001659617
Form:       8-K
Filed at:   2026-02-17T23:59:59+00:00
Accession:  0001437749-26-004236
Event type: regulatory
Sentiment:  positive
Materiality: 0.60
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Moleculin gets Japanese patent allowance for Annamycin reconstitution methods
-----------------------------------------------------------------------------

- Japan Patent Office issued notice of allowance for Patent App. 2021-577862 covering liposomal Annamycin preparation methods.
- Patent expected to issue in coming months; complements existing US and European Annamycin patents.
- Annamycin (naxtarubicin) is in Phase 3 for relapsed/refractory AML with FDA Fast Track and Orphan Drug designations.
- CEO Klemp states the allowance strengthens international IP for non-cardiotoxic anthracycline therapy.
- Additional Annamycin-related patent applications are pending in major jurisdictions worldwide.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1659617/000143774926004236/0001437749-26-004236-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1659617/000143774926004236/mbrx20260216_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-26-004236

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer